

Special Issue

Most Advanced Therapeutic Agents Redefining Neurological Health

Message from the Guest Editor

Recent clinical trials have established several novel therapeutics as practice-changing interventions in neurology. Regarding the treatment of Alzheimer's disease, anti-amyloid monoclonal antibodies (lecanemab, donanemab) now demonstrate the statistically significant slowing of cognitive decline (CDR-SB 27–35%) in phase 3 trials when initiated at early disease stages. Parkinson's therapeutics now include targeted agents like safinamide (MAO-B/glutamate modulation), showing improved motor fluctuations in extension studies, while subcutaneous apomorphine infusion provides effective rescue therapy. In MS, CD20-depleting therapies (ocrelizumab, ofatumumab) achieve 85–90% relapse reduction with manageable infection risks. For SMA, onasemnogene abeparvovec produces 90% survival without ventilation at 24 months when administered presymptomatically. These advances mandate updated treatment algorithms, emphasizing (1) earlier biomarker-guided intervention, (2) combination approaches, and (3) rigorous monitoring for ARIA (amyloid therapies) and IRIS (immune reconstitution) effects.

Guest Editor

Dr. Clarissa Fantin Cavarsan

Neuroscience and Behavior Program, Wesleyan University, Middletown, CT 06459, USA

Deadline for manuscript submissions

closed (15 April 2026)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/250990

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).